ESR1 and neoplasm: However, standard of care includes immunohistochemical (IHC) evaluation of only the largest tumor for the expression of the estrogen/progesterone receptors (ER/PR), human epidermal growth factor 2 (HER2), and the proliferation marker Ki-67.